Roivant Sciences Ltd.-owned Dermavant Sciences Ltd. appears closer to bringing its first commercial product, tapinarof, to market after two Phase III clinical trials testing the novel topical cream met the primary endpoints in psoriasis. Dermavant announced positive data from the studies on 26 August along with plans to complete a regulatory filing for tapinarof with the US Food and Drug Administration in the first half of 2021.
Dermavant's Tapinarof Could Bring Innovation To Topical Psoriasis Market
CEO Todd Zavodnick said the non-steroidal topical cream is poised to become a blockbuster brand.
More from Dermatological
• By
CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.
• By
Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.
• By
Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.
• By
Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.